Stay updated on Cabozantinib & 13-cisRA in Children Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib & 13-cisRA in Children Clinical Trial page.

Latest updates to the Cabozantinib & 13-cisRA in Children Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov page now displays site revision v3.8.1 instead of v3.8.0.SummaryDifference0.1%

- Check8 days agoChange DetectedThe ClinicalTrials.gov record for a Phase 1 study of cabozantinib with 13-cis-retinoic acid in children with relapsed or refractory solid tumors is now displayed. It includes the study design, eligibility criteria, treatment details, outcome measure, locations, and completion status.SummaryDifference44%

- Check15 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedA general NIH notice about the terminology transition appears above the 403 error page, and the site revision advances from v3.7.1 to v3.7.2.SummaryDifference1%

- Check43 days agoChange DetectedThe footer now displays site revision v3.7.1 instead of v3.7.0. The page continues to show a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check50 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the expected study record, indicating an access or server issue that prevents viewing the study content.SummaryDifference0.5%

Stay in the know with updates to Cabozantinib & 13-cisRA in Children Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib & 13-cisRA in Children Clinical Trial page.